Free Trial
→ This Cold War “Accident” Could Unleash New $100 Trillion AI Boom (From Brownstone Research) (Ad) Free BCTX Stock Alerts

Briacell Therap (BCTX) News Today

Briacell Therap logo
$2.02 -0.05 (-2.42%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.98 -0.03 (-1.73%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

BCTX Latest News

BriaCell's Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
July 11 at 7:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/11/3113933/0/en/briacell-s-bria-imt-demonstrates-survival-advantage-over-trodelvy-and-control-group-in-metastatic-breast-cancer.html
BriaCell Reports Complete and Sustained Resolution of Brain Metastasis and Sustained Regression of Orbital Metastasis in “Eye-Bulging” Breast Cancer Patient
July 10, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/10/3113141/0/en/briacell-reports-complete-and-sustained-resolution-of-brain-metastasis-and-sustained-regression-of-orbital-metastasis-in-eye-bulging-breast-cancer-patient.html
BriaCell Patient Achieves Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Metastatic Breast Cancer Study
July 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/09/3112460/0/en/briacell-patient-achieves-sustained-complete-resolution-of-lung-metastasis-in-bria-ots-metastatic-breast-cancer-study.html
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
July 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/08/3111624/0/en/briacell-phase-2-survival-achievement-52-of-patients-surpass-one-year-milestone-in-metastatic-breast-cancer.html
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
July 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/02/3109090/0/en/briacell-highlights-additional-phase-3-clinical-sites-including-los-angeles-cancer-network-and-smilow-cancer-hospital-at-yale-new-haven.html
BCTX BriaCell Therapeutics Corp. - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/BCTX
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
June 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/24/3104139/0/en/briacell-announces-positive-recommendation-from-data-safety-monitoring-board-for-pivotal-phase-3-study-in-metastatic-breast-cancer.html
BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26
June 4, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/04/3093465/0/en/briacell-announces-virtual-investor-presentations-on-thursday-june-12-and-thursday-june-26.html
BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025
June 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/02/3091756/0/en/briacell-reports-robust-overall-survival-and-clinical-benefit-data-at-asco-2025.html
BriaCell Bria-OTS™ Phase 1/2 Study Clears Safety Evaluation; Doses First Patient in Combination with Checkpoint Inhibitor
May 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/27/3088507/0/en/briacell-bria-ots-phase-1-2-study-clears-safety-evaluation-doses-first-patient-in-combination-with-checkpoint-inhibitor.html
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
May 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/23/3087418/0/en/briacell-abstracts-showcase-positive-survival-and-clinical-benefit-data-at-asco-2025.html
BriaCell Therapeutics Corp.: BriaCell CEO Letter to Shareholders
May 20, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65456251-briacell-therapeutics-corp-briacell-ceo-letter-to-shareholders-399.htm
BriaCell CEO Letter to Shareholders
May 20, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/20/3084743/0/en/briacell-ceo-letter-to-shareholders.html
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
April 30, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/30/3071242/0/en/briacell-reports-late-breaker-phase-3-data-at-aacr-2025-positive-tolerability-profile-and-potential-response-biomarkers-identified.html
BriaCell Therapeutics Announces Closing of $13.8 million Public Offering
April 28, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/28/3069646/0/en/briacell-therapeutics-announces-closing-of-13-8-million-public-offering.html
BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development
April 28, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/28/3069089/0/en/briacell-presents-benchmark-beating-survival-and-clinical-benefit-at-aacr-2025-advancements-in-next-generation-bria-ots-development.html
BriaCell 3.07M share Secondary priced at $4.50
April 25, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/briacell-3-07m-share-secondary-priced-at-4-50-1034624975
BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
April 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/25/3068036/0/en/briacell-therapeutics-announces-pricing-of-13-8-million-public-offering.html
BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS™
April 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/24/3067304/0/en/briacell-confirms-100-resolution-of-lung-metastasis-with-bria-ots.html
BriaCell Announces Four Clinical Data Presentations at ASCO 2025
April 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/23/3066273/0/en/briacell-announces-four-clinical-data-presentations-at-asco-2025.html
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
April 22, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/22/3065391/0/en/briacell-enrollment-pace-accelerating-in-phase-3-clinical-study-in-advanced-metastatic-breast-cancer-bria-abc.html
BriaCell announces survival data from its Phase 2 study of Bria-IMT
April 17, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/briacell-announces-survival-data-from-its-phase-2-study-of-bria-imt-1034591300
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
April 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/16/3062447/0/en/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer.html
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
March 26, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/26/3049653/0/en/briacell-to-present-clinical-and-preclinical-data-at-the-2025-aacr-conference.html
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell's Phase 3 Study in Metastatic Breast Cancer
March 20, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/20/3046182/0/en/second-data-safety-monitoring-board-issues-positive-recommendation-to-continue-briacell-s-phase-3-study-in-metastatic-breast-cancer.html
Vascular health doctor in clinical laboratory for medical research and development concepts. and science with a microscope and a test tube placed beside it - stock image
Biotechs on the Brink: 2 Stocks With Huge Potential
BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.
February 14, 2025  |  marketbeat.comhttps://www.marketbeat.com/stock-ideas/biotechs-on-the-brink-2-stocks-with-huge-potential/
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
February 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/02/05/3021661/0/en/briacell-therapeutics-corp-announces-results-of-shareholder-meeting.html
BriaCell Therapeutics Announces Closing of Public Offering
February 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/02/05/3021594/0/en/briacell-therapeutics-announces-closing-of-public-offering.html
H.C. Wainwright raises Briacell stock target to $32 on trial success
February 4, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/hc-wainwright-raises-briacell-stock-target-to-32-on-trial-success/ar-AA1yotyj
BriaCell Therapeutics Announces Pricing of Public Offering
February 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/02/04/3019942/0/en/briacell-therapeutics-announces-pricing-of-public-offering.html
BriaCell announces public offering of common shares
February 3, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/briacell-announces-public-offering-of-common-shares/ar-AA1ym5B5
BriaCell Therapeutics stock rises on positive clinical trial results
February 3, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/briacell-therapeutics-stock-rises-on-positive-clinical-trial-results/ar-AA1ykqln
BriaCell Therapeutics trading halted, volatility trading pause
February 3, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/briacell-therapeutics-trading-halted-volatility-trading-pause-1034304006
BriaCell Therapeutics Drops 4% Following Metastatic Breast Cancer Trial Results
February 3, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/briacell-therapeutics-drops-4-following-metastatic-breast-cancer-trial-results-1034304975
BriaCell Therapeutics Announces Proposed Public Offering of Common Shares
February 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/02/03/3019898/0/en/briacell-therapeutics-announces-proposed-public-offering-of-common-shares.html
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™
February 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/02/03/3019425/0/en/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots.html
BCTX stock touches 52-week low at $0.37 amid sharp yearly decline
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/bctx-stock-touches-52-week-low-at-037-amid-sharp-yearly-decline/ar-AA1y0Hxi
BriaCell Announces Completion of 15:1 Share Consolidation
January 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/01/27/3016038/0/en/briacell-announces-completion-of-15-1-share-consolidation.html
BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
December 17, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/17/2998627/0/en/briacell-announces-availability-of-annual-general-meeting-materials-and-alternative-voting-procedures.html
BriaPro Therapeutics Corp. Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures
December 17, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/17/2998623/0/en/briapro-therapeutics-corp-announces-availability-of-annual-general-meeting-materials-and-alternative-voting-procedures.html
BriaCell Therapeutics Announces Closing of $5.5 Million Public Offering
December 13, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/13/2997040/0/en/briacell-therapeutics-announces-closing-of-5-5-million-public-offering.html
BriaCell 2024 SABCS® Poster Highlights Ability of Bria-IMT™ Regimen to Increase Cancer-Fighting Immune Cells in Metastatic Breast Cancer
December 13, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/13/2996746/0/en/briacell-2024-sabcs-poster-highlights-ability-of-bria-imt-regimen-to-increase-cancer-fighting-immune-cells-in-metastatic-breast-cancer.html
BriaCell Therapeutics (NASDAQ:BCTX) Stock, Short Interest Report
December 12, 2024  |  benzinga.comhttps://www.benzinga.com/quote/BCTX/short-interest
Why BriaCell Therapeutics (BCTX) Stock Is Down 40%
December 12, 2024  |  benzinga.comhttps://www.benzinga.com/news/24/12/42470201/why-briacell-therapeutics-bctx-stock-is-down-40
BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering
December 11, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/12/2995866/0/en/briacell-therapeutics-announces-pricing-of-5-5-million-public-offering.html
BriaCell Therapeutics Announces Proposed Public Offering
December 11, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/11/2995748/0/en/briacell-therapeutics-announces-proposed-public-offering.html
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
December 11, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/11/2995320/0/en/briacell-presents-unprecedented-overall-survival-data-in-metastatic-breast-cancer-in-spotlight-poster-at-2024-sabcs.html
BriaCell says DSMB recommends continuation of Phase 3 study in MBC
December 3, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/briacell-says-dsmb-recommends-continuation-of-phase-3-study-in-mbc-1034087094
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
December 2, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/12/02/2989718/0/en/briacell-receives-green-light-from-data-safety-monitoring-board-for-its-phase-3-study-in-metastatic-breast-cancer.html
BriaCell to highlight OS, clinical benefit data of Bria-IMT in MBC patients
November 26, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/briacell-to-highlight-os-clinical-benefit-data-of-bria-imt-in-mbc-patients-1034066866
Get Briacell Therap News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.

BCTX Media Mentions By Week

BCTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BCTX
News Sentiment
▼
0.38

1.01
▲
Average
Medical
News Sentiment

BCTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BCTX Articles
This Week
▼
5

1
▲
BCTX Articles
Average Week

Get Briacell Therap News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies
Headlines Tools

This page (NASDAQ:BCTX) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...
American Alternative | Sponsored
Elon’s NEXT Big IPO?
Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...
Banyan Hill Publishing | Sponsored
Special gold investment soars 2,300% ... 5,090% ... 9,850%
In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...
Weiss Ratings | Sponsored
Trump’s biggest move, misreported
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...
Porter & Company | Sponsored
Which Gold Miner Trades at 30% of NAV? The One Buffett Wants
Some of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...
Golden Portfolio | Sponsored
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored